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Now for the “complexity issue,” which I believe is Pro-
fessor Emmett’s major criticism of Stewart’s theory. Just
as Newtonian physics may be regarded as a subset of
Einstein’s relativity, the traditional model of acid-base
balance may be thought of as a subset of Stewart’s
more general theory. Professor Emmett is correct in that
both Newtonian physics and traditional acid-base theory
are useful to describe commonly observed phenomenon.
However, in actuality, light bends and so does the buffer
curve. In the era of the palmtop computer, mathematical
complexity should not impede progress either in physics
or in physiology.
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CD28− T cells display features
of effector memory T cells in
Wegener’s granulomatosis
To the Editor: We read with interest the article by Vogt
et al [1], who found shortening of telomers and reduced
CD28 expression on T-cells in Wegener’s granulomatosis
(WG). Several groups have shown an expansion of cir-
culating CD8+ and CD4+ T-cells lacking the costimula-
tory molecule CD28 in WG. The expansion of circulating
CD28− T-cells is already evident in patients with initial
disease manifestations and correlates with organ involve-
ment [2]. CD4+CD28− and CD8+CD28− T-cells are en-
riched in broncho-alveolar lavage fluid. In granulomatous
lesions of the respiratory tract in WG, T-cells completely
lack CD28 expression. Circulating peripheral blood and
granuloma CD4+CD28− T-cells are a major source of
Th1-type cytokine secretion [3]. The Th1-type chemokine
receptor CCR5 is expressed on CD28− T-cells and may
favor recruitment of CD28− T-cells into inflammatory le-
sions [2]. Of note, circulating CD4+CD28− T-cells ex-
press the differentiation marker CD57 (HNK-1) and the
activation marker CD18 (b2-integrin). The expression of
these cell surface markers and the restriction of Th1-type
cytokine production to IFN-c and TNF-a and perforin
expression of CD4+CD28− T-cells in WG is typical of so-
called late differentiated or effector memory T-cells [3].
Shortening of telomer length as a sign of replicative senes-
cence of T-cells is in line with the finding of an expanded
subset of effector memory T-cells. CD8+CD28− cells dis-
play heterogeneous CD27 expression, features which are
also seen in antigen-specific (cytomegalovirus-) T-cells in
WG, but not in controls, suggesting profound generalized
changes in the CD8+ T-cell compartment also affecting
virus-specific T-cell responses in WG [4].
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Reply from the Authors
We appreciate the comment and the reference to
the publications—cited as [2] and [4]—which were not
yet available when we were submitting our manuscript.
Basically, we agree that there are small numbers of
CD4+CD28− T-cells in patients with Wegener’s gran-
ulomatosis (5.4% as cited by Lamprecht et al [1] and
approximately 3% in our study). The more intriguing
finding of our study, however, is that the majority of
CD28− cells are CD8+ T-cells. They amount to 60% in
some patients (mean 45.2 ± 15.5, N = 22). Since sub-
mission of our manuscript, several publications dealing
with the identification of CD28− T-cells have appeared,
and there is now increasing evidence that these represent
memory/effector cells [2, 3]. Following antigenic chal-
lenge, naive T-cells enter a program of differentiation and
proliferation, and ultimately become memory cells. These
cells do not have short telomeres; there is, however, evi-
dence for increased division rates, as seen by reduced lev-
els of T-cell receptor excision cycles [4]. It is reasonable to
assume that during long-term, severe chronic inflamma-
tory disease, as in Wegener’s granulomatosis, these cells
eventually reach their finite number of cell divisions and
enter a state of senescence associated with shortening of
the telomeres. This assumption is in accordance with the
data derived from studies on persistent (virus) infection
[3, 5].
1114 Letters to the Editor
Of note is that senescent T-cells do not express CD28,
but that, on the other hand, not all CD28− T-cells are
senescent.
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The impact of antiretroviral
therapy on HIVAN
To the Editor: We read with interest the article by
Wei et al [1] on the association between anigotensin-
converting enzyme inhibition (ACE-I) and outcomes
among patients with human immunodeficiency virus–
associated nephropathy (HIVAN). We are concerned
about the inherent limitations in making concrete con-
clusions from observational data and would caution
nephrologists against relying too heavily on ACEI, while
de-emphasizing the role of antiretroviral therapy (ARV)
in the treatment of HIVAN. The authors show that fos-
inopril, not ARV, is an important predictor of mortality.
With the introduction of highly active antiretroviral ther-
apy (HAART), the survival benefit from ARV therapy is
indisputable. Failure to show such a benefit raises impor-
tant questions about the data; specifically, what classes
of ARV were available during the course of this study.
In the absence of more information in this regard, it is
conceivable that the benefits of ACE-I, which decreased
the risk of death 100-fold, may be overstated.
The cohort was recruited between 1993–1997 before
the availability of HAART, and the current work rep-
resents long-term follow-up of the original survivors.
Only 16 patients were followed for more than one year,
minimally overlapping the contemporary era in which
HAART has so significantly improved survival. Most of
these patients were treated with ACE-I and were orig-
inally coded as not taking ARV. Because most of the
deaths occurred within the first year of enrollment, it
would not be fair to ascribe long-term benefits of sur-
vivors to ACE-I if, in fact, survivors had access to potent
ARV, such as HAART, years after they were coded as
not having been treated at baseline. Another concern is
the observation that the cohort includes 11 patients who
survived but were followed for less than one year. All 11
of these patients were taking ARV. Said another way, sur-
vivors not taking ARV were followed for 1200 days, while
survivors taking ARV were followed for only 385 days.
There seems to be considerable nonrandom loss to
follow-up in the ARV group, which by itself would skew
the data to more favorable outcomes for ACE-I. Bias
could also be introduced by factors not included in this
analysis, such as perceptions about patient compliance,
which could influence the decision to begin antiretrovi-
ral therapy or ACE-I, HIV RNA levels, and how CD4
count and HIV RNA levels change over time with ARV.
Finally, nonrandom misclassification bias likely impacted
the significance of ARV on outcomes. The definition of
ARV exposure is ≥30 consecutive days. This is not suffi-
cient exposure to derive any meaningful benefit from the
drugs, yet patients with minimal exposure could easily
have been labeled as having been treated.
Therefore, for these reasons, we do not believe these
data can assess the impact of ARV on renal outcomes
among patients with HIVAN. Given prior reports which
suggest that increasing CD4 lymphocyte counts and non-
detectable HIV RNA levels are associated with better
renal outcomes [2, 3], and the trend toward greater use
of antiretroviral medications in the group receiving fos-
inopril, we believe that the real question not addressed
by these data becomes “Does disrupting the renin-
angiotensin system affect the progression of HIVAN
among patients with effective suppression of viral
replication?”
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